(Q42722363)

5 November 2017

title

Genetic polymorphisms are associated with variations in warfarin maintenance dose in Han Chinese patients with venous thromboembolism (English)

1 reference

5 November 2017

1 reference

Wei Zhang

1

1 reference

5 November 2017

Wei-Juan Zhang

2

1 reference

5 November 2017

Jin Zhu

3

1 reference

5 November 2017

Fan-Cui Kong

4

1 reference

5 November 2017

Yan-Yan Li

5

1 reference

5 November 2017

He-Yao Wang

6

1 reference

5 November 2017

Yuan-Hua Yang

7

1 reference

5 November 2017

Chen Wang

8

1 reference

5 November 2017

publication date

17 January 2012

1 reference

5 November 2017

1 reference

5 November 2017

volume

13

1 reference

5 November 2017

issue

3

1 reference

5 November 2017

page(s)

309-321

1 reference

Evaluation of genetic factors for warfarin dose prediction

5 November 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

The largest prospective warfarin-treated cohort supports genetic forecasting

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

Pharmacogenomics and drug toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

Biochemistry and molecular biology of the human CYP2C subfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

CYP2C9 polymorphism and warfarin sensitivity in Taiwan Chinese

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

Association of warfarin dose with genes involved in its action and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

Homozygosity mapping of a second gene locus for hereditary combined deficiency of vitamin K-dependent clotting factors to the centromeric region of chromosome 16.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

Common VKORC1 and GGCX polymorphisms associated with warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

Pharmacogenetic impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a hispanic population isolate.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

ARMS test for diagnosis of CYP2C9 and VKORC1 mutation in patients with pulmonary embolism in Han Chinese

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

Genetic factors contribute to patient-specific warfarin dose for Han Chinese

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

Human CYP1A1 variants lead to differential eicosapentaenoic acid metabolite patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

Manganese superoxide dismutase and cytochrome P450 1A1 genes polymorphisms in rheumatoid arthritis in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

CYP1A2 phenotype and genotype in a population from the Carboniferous Region of Coahuila, Mexico

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

VKORC1 Asp36Tyr warfarin resistance marker is common in Ethiopian individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

A new VKORC1 mutation leading to an isolated resistance to fluindione.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

Comparison of cytochrome P450 2C9 genotyping methods and implications for the clinical laboratory

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

The influence of ethnicity on warfarin dosage requirement

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

VKORC1 diplotype-derived dosing model to explain variability in warfarin dose requirements in Asian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

Genetic and clinical predictors of warfarin dose requirements in African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.147

21 January 2018

Identifiers

DOI

10.2217/PGS.11.147

1 reference

5 November 2017

1 reference